Impatiens

by | Dec 19, 2023 | Impatiens

How Can We Help?
You are here:
< Back

Lysophosphatidylinositol (LPI, lysoPI), or L-α-lysophosphatidylinositol, is an endogenous lysophospholipid and endocannabinoid neurotransmitter.[1] LPI, along with its 2-arachidonoyl- derivative, 2-arachidonoyl lysophosphatidylinositol (2-ALPI), have been proposed as the endogenous ligands of GPR55.[2][3][4][5]

See also

References

  1. ^ Li X, Wang L, Fang P, et al. (May 2018). "Lysophospholipids induce innate immune transdifferentiation of endothelial cells, resulting in prolonged endothelial activation". The Journal of Biological Chemistry. 293 (28): 11033–11045. doi:10.1074/jbc.RA118.002752. PMC 6052225. PMID 29769317.
  2. ^ Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T (November 2007). "Identification of GPR55 as a lysophosphatidylinositol receptor". Biochemical and Biophysical Research Communications. 362 (4): 928–34. doi:10.1016/j.bbrc.2007.08.078. PMID 17765871.
  3. ^ Henstridge CM, Balenga NA, Ford LA, Ross RA, Waldhoer M, Irving AJ (January 2009). "The GPR55 ligand L-alpha-lysophosphatidylinositol promotes RhoA-dependent Ca2+ signaling and NFAT activation". The FASEB Journal. 23 (1): 183–93. doi:10.1096/fj.08-108670. PMID 18757503. S2CID 27142069.
  4. ^ Piñeiro, Roberto; Falasca, Marco (2012). "Lysophosphatidylinositol signalling: New wine from an old bottle". Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 1821 (4): 694–705. doi:10.1016/j.bbalip.2012.01.009. PMID 22285325.
  5. ^ Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T (January 2009). "2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55". Journal of Biochemistry. 145 (1): 13–20. doi:10.1093/jb/mvn136. PMID 18845565.


Categories
Table of Contents